Tumor-Absorbed Dose Predicts Progression-Free Survival Following ¹³¹I-Tositumomab Radioimmunotherapy

Abstract

A higher mean tumor-absorbed dose was significantly predictive of improved PFS after (131)I-tositumomab radioimmunotherapy. Hence tumor-absorbed dose, which can be estimated before therapy, can potentially be used to design radioimmunotherapy protocols to improve efficacy.